证券代码：688202 证券简称：美迪西 公告编号：2025-036 上海美迪西生物医药股份有限公司 关于以集中竞价交易方式回购公司股份比例达到 1% 暨回购进展公告 回购方案实施期限 待公司股东大会审议通过后 6 个月 预计回购金额 5,000万元~10,000万元 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： √减少注册资本 回购方案首次披露日 2024/12/28，由公司实际控制人、时任董事长陈金 章先生，实际控制人、时任董事、总经理 √用于员工持股计划或股权激励 CHUN-LIN CHEN 先生提议 回购用途 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购期间，回购股份占公司总股本的比例 每增加 1%的，应当在事实发生之日起 3 个交易日内予以披露。现将公司回购股份 进展情况公告如下： 截至 2025 年 5 月 28 日，公司通过上海证券交易所系统以集中竞价交易方式 已累计回购公司股份 1,346,910 股，已回购股份占公司总股本 ...

Core Viewpoint - The event aims to explore the development trends and investment opportunities in the biopharmaceutical industry, facilitating deep communication between the industry and capital markets, and breaking down information barriers [1][3]. Group 1: Event Overview - The 13th session of the Lujiazui Financial Salon will be held on May 30 in Shanghai, focusing on "Capital Driving the Leap of the Biopharmaceutical Industry" [3]. - The event invites prominent guests from the scientific, industrial, and capital sectors to discuss the biopharmaceutical industry's development trends and investment opportunities [1][3]. Group 2: Key Speakers - Yuan Quanhong, founder and CEO of Hankan Capital, has over 20 years of experience in the pharmaceutical field and has led investment decisions for over 40 projects, many of which have become industry leaders [3]. - Ma Dawei, an academician of the Chinese Academy of Sciences, has long engaged in basic research and innovative drug development in the biopharmaceutical field, receiving multiple prestigious awards [6]. - Xu Yaochang, founder and CEO of Heyu Pharmaceutical, has over 25 years of experience in new drug research and management, leading numerous innovative drug projects across various disease areas [11]. - Bai Jiajie, investment director at Taibao Private Equity Fund Management Co., has 18 years of experience in capital markets, leading over $15 billion in overseas IPOs and significant cross-border mergers and acquisitions [14]. - Yang Ying, head of strategy and business development for Sanofi Greater China, has 20 years of experience in the pharmaceutical industry, covering various fields including strategic planning and drug development [17]. Group 3: Discussion Topics - The dialogue will focus on collaborative development between the biopharmaceutical industry and capital, discussing topics such as technological breakthroughs, enterprise growth paths, capital demands, and the integration of industry and academia [20]. - The event aims to provide practical suggestions for the deep integration of industry and capital through cross-disciplinary discussions [20]. Group 4: Event Support and Goals - The Lujiazui Financial Salon is guided by the Shanghai Municipal Financial Office and the People's Government of Pudong New District, with media support from various financial news outlets [21]. - The series of events serves as a regular communication platform, aiming to continuously contribute to financial reform and support the high-quality development of the Pudong economy [21].

来源：中国新闻网 研究发现，癌细胞能够通过一种名为巨胞饮—蛋白酶体降解途径的营养代偿系统来获取外部蛋白质，并 将其分解成氨基酸，以便在缺乏营养的情况下生存。基于这一发现，研究团队设计了一种特殊的纳米粒 子，能够释放药物来阻止癌细胞内吞及降解这些蛋白质，从而实现高效的肿瘤饥饿治疗。 该研究获得国家自然科学基金(优秀青年科学基金项目)支持。有关研究成果已在国际学术期刊Advanced Science发表，并已提交美国专利申请。 根据2022年香港癌症统计数据，肺癌仍是香港最常见的癌症，占香港癌症新症总数的16.1%。这类肿瘤 由于其内部缺乏血液供应，容易形成营养缺乏的肿瘤微环境，导致氨基酸和葡萄糖等重要的营养成分不 足。 在这项研究中，团队发现癌细胞的巨胞饮—蛋白酶体降解过程可以作为细胞外蛋白质内化和降解的一种 途径。汪卫平表示，这一新机制提示巨胞饮—蛋白酶体降解体系可成为另一种肿瘤饥饿治疗的关键靶 点。此外，为促进该策略的临床转化，研究团队开发了一种新型pH响应性聚合物纳米粒子来抑制癌细 胞的氨基酸水平，从而达到肿瘤饥饿治疗的效果。(完) 中新社香港5月28日电 香港大学医学院(简称"港大医学院")28日宣布， ...

Core Insights - The article highlights the potential of AI-driven drug discovery, specifically focusing on the development of ISM5939, a small molecule inhibitor targeting ENPP1 to enhance tumor immunity and overcome resistance to existing therapies [1][2][3] Group 1: AI-Driven Drug Development - Insilico Medicine has published its third AI-driven drug development research in a Nature journal since 2025, showcasing the integration of advanced generative AI platforms in drug discovery [1][3] - The research emphasizes the use of AI to identify and validate the role of ENPP1 in various solid tumors, leading to the development of the highly specific oral ENPP1 inhibitor ISM5939 [2][3] Group 2: Mechanism and Efficacy of ISM5939 - ISM5939 targets ENPP1 to precisely regulate the STING signaling pathway within tumor tissues, restoring local immune activation and enhancing anti-tumor immune responses [1][6] - The study confirms that ENPP1 inhibitors can overcome dual resistance to immune checkpoint inhibitors and chemotherapy, providing new treatment hope for refractory cancer patients [1][6] Group 3: Clinical Development and Future Prospects - ISM5939 has shown promising preclinical data, demonstrating enhanced efficacy when combined with various therapies, including anti-PD-1 treatments and chemotherapy [9] - The FDA granted clinical trial approval for ISM5939 in November 2024, marking a significant milestone in its development [9] - The research team aims to inspire the industry with their findings, potentially leading to new generations of innovative cancer therapies [9][10]

Core Viewpoint - The agreements signed by BetaMind Investments Limited are strategic moves to leverage valuable intellectual property and enter promising new business areas, integrating artificial intelligence and robotics into their operations [1][3]. Group 1: Agreements and Licenses - BetaMind entered into three final agreements on May 26, 2025, including a trademark licensing agreement and two exclusive licensing agreements for specific compounds [1]. - The trademark licensing agreement allows BetaMind to use trademarks related to the "Groland" brand [1]. - The exclusive licensing agreements grant BetaMind rights to use specific compounds XTP-016 and XTP-018 globally, including sublicensing rights [2]. Group 2: Strategic Planning and Business Development - The board believes that these agreements present valuable opportunities for the group, allowing for the appropriate utilization of the target trademarks and licensing rights [3]. - The company is developing a budget for additional investments aimed at establishing new business areas, covering key aspects such as human resources, production facilities, and marketing plans [3]. - The board is confident that these new business initiatives will enhance the group's long-term growth potential and diversify its revenue sources [3].

Group 1 - The article highlights that there are approximately 600 stocks in the A-share market with a market capitalization of less than 2 billion yuan, some of which have high growth potential despite low performance [1] - It emphasizes the importance of a discerning approach to small-cap stocks, suggesting that companies with potential should be bought and held in a diversified manner, while poorly performing companies should be avoided [1][2] - Examples of promising small-cap companies include those in the biopharmaceutical sector that are overcoming technological challenges and those in emerging tech services that provide intelligent solutions for traditional industries [1] Group 2 - The article warns that some small-cap stocks are struggling due to poor management, intense competition, and lack of core competitiveness, leading to declining performance and stock prices [2] - It stresses the need for investors to conduct thorough research on a company's fundamentals, including financial health, industry position, core competitiveness, and management capabilities [2] - The article advocates for a diversified investment strategy to mitigate risks associated with small-cap stocks, suggesting that investors should not concentrate their funds in a few stocks but rather spread them across multiple small-cap stocks from different industries [3] Group 3 - Overall, the article presents small-cap stocks as a field filled with both opportunities and risks, urging investors to adopt a balanced perspective and engage in rational analysis and decision-making to identify truly valuable investment targets [3]

Core Insights - The Yangtze River Delta (YRD) region's new energy vehicle (NEV) industry achieved significant production in Q1 2025, with over 840,000 vehicles produced, accounting for nearly 30% of the national total, continuing its status as a production hub [1] - The region is transitioning from the "first half of electrification" to the "second half of intelligence," driven by leading companies like CATL, NIO, and Tesla, but faces challenges such as overcapacity, declining penetration rates, and regional collaboration barriers [1][5] Industry Structure and Collaboration - The YRD NEV industry is moving from "local breakthroughs" to a "system layout," with clear functional positioning among Jiangsu, Shanghai, Zhejiang, and Anhui, forming a complete industrial chain from vehicles to batteries, chips, and components [2] - Shanghai is building a head ecosystem around vehicle manufacturing and intelligent driving, with Tesla's Shanghai Gigafactory expected to deliver 910,000 vehicles in 2024, representing nearly half of global capacity [2] - Jiangsu focuses on power batteries, housing over 190 key enterprises, including CATL and BYD, establishing a leading lithium battery production base [2] - Zhejiang's NEV industry cluster is projected to exceed 1 trillion yuan in revenue by 2024, growing by 19.5%, but faces challenges due to reliance on small private enterprises and limited financing [3] - Anhui's NEV production is expected to reach 1.684 million units in 2024, a 94.5% increase, with policies driving growth and establishing a "vehicle-software-testing" ecosystem [3] Challenges in Collaboration and Financial Support - The YRD NEV industry faces collaboration obstacles, including inconsistent data standards and unreasonable capital allocation, hindering cross-regional operations and testing [3][4] - Local industrial funds prioritize local projects, limiting support for cross-regional enterprises, exemplified by Hefei's targeted support for NIO, which has not significantly impacted other cities [4] Transition to Intelligent Systems - The global NEV market is experiencing a slowdown, with penetration rates dropping from 53.2% to 41.5% between September 2024 and January 2025, indicating a need for a shift from manufacturing to intelligent systems [5] - The YRD region has a solid foundation for intelligent transformation, with Shanghai leading in high-end electronic architecture and autonomous driving testing platforms [5][6] - However, the software ecosystem remains fragmented, with strong vehicle and chip companies but weak middleware, limiting the formation of a complete ecosystem [6][7] - To advance the NEV industry into the "second growth curve," the YRD must enhance software collaboration and public support capabilities [7]

Core Viewpoint - The research led by Professor Lu Yuming highlights the impact of chromatin accessibility on the clearance rate of plasma DNA through the kidneys, suggesting new diagnostic methods for diseases with renal manifestations [3][9]. Group 1: Liquid Biopsy and Non-Invasive Testing - Professor Lu Yuming is recognized as a pioneer in the field of liquid biopsy, particularly in non-invasive prenatal testing, having discovered fetal cell-free DNA in maternal blood as early as 1997 [2]. - The non-invasive prenatal diagnostic technology based on DNA analysis has been widely adopted in over 100 countries, benefiting approximately 10 million pregnant women annually [2]. - The recent development of the FRAGMA technology enables the detection of multiple cancers through blood tests, advancing liquid biopsy into the whole-genome era [2]. Group 2: Research Findings on Urinary Cell-Free DNA (ucfDNA) - The study published in the journal Med reveals that chromatin accessibility states affect the renal clearance of plasma DNA, potentially through size limitations of the glomerular barrier [3][9]. - The research identifies two types of ucfDNA: renal ucfDNA (filtered through the kidneys) and urinary tract ucfDNA, highlighting their distinct characteristics [5]. - Analysis of 136 ucfDNA samples from various groups (healthy controls, pregnant women, chronic kidney disease patients, and bladder cancer patients) provided insights into fragmentomic features, including fragment size and 5' end motifs [5][6]. Group 3: Implications for Disease Detection - Renal ucfDNA is primarily derived from open chromatin regions, while urinary tract ucfDNA exhibits unique fragmentomic characteristics [6][7]. - The study indicates that in patients with proteinuria (e.g., preeclampsia, chronic kidney disease), levels of ucfDNA from heterochromatin regions increase, suggesting a correlation with glomerular permeability [6]. - The effectiveness of bladder cancer detection is significantly enhanced by analyzing low methylation signals from heterochromatin regions, achieving an AUC of 0.93 [6]. Group 4: Broader Impact and Recognition - Professor Lu Yuming's contributions to medical science have garnered international accolades, including election to the Royal Society and the National Academy of Sciences, as well as prestigious awards such as the Future Science Prize and the Lasker Award [14]. - His research is considered a strong contender for the Nobel Prize, with significant implications for cancer screening and risk prediction [14].

Core Insights - The article discusses the transformation of Shaoxing Binhai New Area into a hub for agricultural modernization through effective investment and leveraging its geographical advantages, contributing to rural revitalization and economic growth [1][2][3]. Investment and Economic Growth - In 2024, the Binhai New Area achieved significant agricultural project investments totaling 903 million yuan, with an investment completion rate of 237%, and agricultural output surpassing 2.6 billion yuan, leading to a 10.4% increase in per capita income for low-income farmers [1]. - The Long Triangle International Agricultural Wholesale Center, with a total investment of 2.16 billion yuan, aims to become a key logistics hub for agricultural products in the Yangtze River Delta, with expected annual transactions exceeding 10 billion yuan [2]. - The Binhai New Area has seen the emergence of various major projects, including a 2 billion yuan investment in a biopharmaceutical production line and a project converting 180,000 tons of straw into organic substrates [2][3]. Technological Advancements - Digital technologies are reshaping agriculture in the Binhai New Area, with automated systems improving seedling survival rates from 80% to 95%, resulting in an average income increase of 15% for farmers [4]. - The use of data-driven approaches in farming has led to a 30% increase in efficiency in the production of yellow wine, showcasing the shift from traditional methods to smart agriculture [2][5]. Policy and Market Collaboration - The government is fostering a collaborative environment between public and private sectors, providing subsidies for storage, preservation, and processing projects, which has attracted significant social capital [3]. - A 10 billion yuan new momentum fund and land allocation strategies are being implemented to support agricultural projects and enhance local economic development [3]. Cultural and Community Integration - The Binhai New Area is integrating cultural heritage with modern agricultural practices, creating tourism opportunities that have significantly increased local income [6]. - Initiatives like "common prosperity workshops" are helping to create jobs and boost collective economic growth in rural areas, demonstrating a holistic approach to rural revitalization [6][7]. Future Goals - The Binhai New Area aims to establish a 10 billion yuan vegetable processing industry chain and create a national modern agricultural industrial park, focusing on cultivating over a thousand new farmers [7].

Core Insights - The Nanjing Biomedicine Center is enhancing the transformation of early-stage biomedical projects by providing comprehensive support services for research teams from various universities [1][2][3] Group 1: Project Development and Support - The Nanjing Biomedicine Center has selected 1,123 medical research results and has 31 projects currently residing at the center [1] - The center has established a team of over 140 technical managers to facilitate the connection between technology and market needs, engaging with 68 universities nationwide [2] - The center provides high-end equipment, such as over 40 high-resolution mass spectrometers, which are essential for new drug development [3][4] Group 2: Financial and Resource Support - The center has created a funding support system with a scale of 8.4 billion yuan, including various financial instruments like angel funds and bank loans [5] - Quick loan approvals have been reported, with one project receiving 6 million yuan in just two weeks, showcasing the center's proactive financial support [5] - The center offers a range of services including intellectual property support and rapid customs clearance for research materials, aimed at reducing barriers for project teams [6] Group 3: Innovation and Collaboration - The center acts as a bridge for technology transfer and innovation, helping teams to "move in with their bags" and focus on development [4] - Collaboration with various universities and institutions is emphasized, with the center attracting diverse project teams from across the country [2][4] - The center aims to facilitate the transition of research outcomes from academic settings to commercial applications, promoting a dual-directional engagement between universities and enterprises [6]